All In MedTech

Device Trial Radar · NCT05644951

Clinical Trial of EPASS With Hot AXIOS System

A Prospective, Multi-center, Single-arm Study for Unresectable Malignant Gastric Outlet Obstruction With EUS-guided Double-balloon-occluded Gastrojejunostomy Bypass

Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Dec 23, 2022

Primary completion

Dec 5, 2024

Study completion Aug 29, 2025

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Dec 9, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multi-center, single-arm study for unresectable malignant gastric outlet obstruction with EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS)

Conditions

  • Gastric Outlet Obstruction

Interventions

  • Hot AXIOS system used for EPASSDevice

    EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GOOSS 3 rate without MAETime frame: 30 days post index-procedure

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • Teine Keijinkai Hospital

    Sapporo, Hokkaido, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.